EIDX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
EIDX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Operating Margin % is calculated as Operating Income divided by its Revenue. Eidos Therapeutics's Operating Income for the three months ended in Sep. 2020 was $-29.40 Mil. Eidos Therapeutics's Revenue for the three months ended in Sep. 2020 was $0.13 Mil. Therefore, Eidos Therapeutics's Operating Margin % for the quarter that ended in Sep. 2020 was -23,151.97%.
The historical rank and industry rank for Eidos Therapeutics's Operating Margin % or its related term are showing as below:
Eidos Therapeutics's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.
Eidos Therapeutics's Operating Income for the three months ended in Sep. 2020 was $-29.40 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Sep. 2020 was $-99.85 Mil.
The historical data trend for Eidos Therapeutics's Operating Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Eidos Therapeutics Annual Data | |||||||||
Trend | Dec16 | Dec17 | Dec18 | Dec19 | |||||
Operating Margin % | - | - | - | -151.55 |
Eidos Therapeutics Quarterly Data | ||||||||||||||||
Dec16 | Mar17 | Jun17 | Sep17 | Dec17 | Mar18 | Jun18 | Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | |
Operating Margin % | Get a 7-Day Free Trial | 23.42 | - | - | - | -23,151.97 |
For the Biotechnology subindustry, Eidos Therapeutics's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Eidos Therapeutics's Operating Margin % distribution charts can be found below:
* The bar in red indicates where Eidos Therapeutics's Operating Margin % falls into.
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
Eidos Therapeutics's Operating Margin % for the fiscal year that ended in Dec. 2019 is calculated as
Operating Margin % | = | Operating Income (A: Dec. 2019 ) | / | Revenue (A: Dec. 2019 ) |
= | -40.451 | / | 26.691 | |
= | -151.55 % |
Eidos Therapeutics's Operating Margin % for the quarter that ended in Sep. 2020 is calculated as
Operating Margin % | = | Operating Income (Q: Sep. 2020 ) | / | Revenue (Q: Sep. 2020 ) |
= | -29.403 | / | 0.127 | |
= | -23,151.97 % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Eidos Therapeutics (NAS:EIDX) Operating Margin % Explanation
Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.
Be Aware
Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).
If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.
For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokias Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).
Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.
Thank you for viewing the detailed overview of Eidos Therapeutics's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
Uma Sinha | director, officer: Chief Scientific Officer | C/O EIDOS THERAPEUTICS, INC., 101 MONTGOMERY STREET, SUITE 2550, SAN FRANCISCO CA 94101 |
Franco Valle | officer: Senior Vice President, Finance | 999 SKYWAY ROAD, SUITE 150, SAN CARLOS CA 94070 |
Cameron Turtle | officer: Chief Business Officer | C/O EIDOS THERAPEUTICS, INC., 101 MONTGOMERY STREET, SUITE 2550, SAN FRANCISCO CA 94104 |
Jonathan C Fox | officer: See Remarks | C/O MYOKARDIA, INC., 333 ALLERTON AVENUE, SOUTH SAN FRANCISCO CA 94080 |
Suzanne Sawochka Hooper | director | C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2 |
Douglas Rohlen | director | 3600 HOLLY LANE NORTH, SUITE 40 PLYMOUTH MN 55447 |
Eric Aguiar | director | 888 7TH AVENUE, 12TH FLOOR, NEW YORK NY 10106 |
Rajeev M. Shah | director | 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116 |
Ali J. Satvat | director, 10 percent owner | C/O KOHLBERG KRAVIS ROBERTS & CO., 2800 SAND HILL ROAD, SUITE 200, MENLO PARK CA 94025 |
William Lis | director | PORTOLA PHARMACEUTICALS, INC., 270 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080 |
Christine Siu | officer: CFO and Secretary | C/O EIDOS THERAPEUTICS, INC., 101 MONTGOMERY STREET, SUITE 2550, SAN FRANCISCO CA 94101 |
Bridgebio Pharma, Inc. | 10 percent owner | 421 KIPLING STREET PALO ALTO CA 94301 |
Neil Kumar | director, 10 percent owner, officer: Chief Executive Officer | C/O BRIDGEBIO PHARMA, INC., 3160 PORTER DR, STE 250, PALO ALTO CA 94304 |
Hoyoung Huh | director | C/O NEKTAR THERAPEUTICS, 201 INDUSTRIAL ROAD, SAN CARLOS CA 94070 |
Peter Kolchinsky | 10 percent owner | 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116 |
From GuruFocus
By PRNewswire PRNewswire • 10-14-2020
By PRNewswire PRNewswire • 12-04-2020
By PRNewswire PRNewswire • 10-31-2020
By PRNewswire PRNewswire • 10-06-2020
By PRNewswire PRNewswire • 10-06-2020
By Marketwired Marketwired • 01-04-2021
By PRNewswire PRNewswire • 11-12-2020
By Marketwired Marketwired • 10-09-2020
By PRNewswire PRNewswire • 11-14-2020
By Marketwired Marketwired • 10-06-2020
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.